TimesSquare Capital Management's U.S. Small Cap Growth Strategy investor letter for Q1 2024 shows a 5.77% return, with top pick Ascendis Pharma A/S (NASDAQ:ASND) gaining. The company's operating loss decreased due to increased revenue and lower expenses.